Anika Therapeutics (ANIK) Acquisitions (2020 - 2021)
Anika Therapeutics' (ANIK) quarterly Acquisitions came in at $113000.0 in Q4 2021, down 84.77% year-on-year from $742000.0 in Q4 2020, and up 927.27% on a QoQ basis from $11000.0 in Q3 2021.
Anika Therapeutics (ANIK) Acquisitions (2020 - 2021) Analysis & Trends
Anika Therapeutics (ANIK) has 2 years of Acquisitions data on file, last reported at $113000.0 in Q4 2021.
- On a quarterly basis, Acquisitions fell 84.77% year-over-year to $113000.0 in Q4 2021; TTM through Sep 2022 was $113000.0, a 89.77% decrease from a year earlier, with the FY2021 full-year figure at $476000.0, down 99.5% from the prior year.
- Acquisitions for Q4 2021 stood at $113000.0, up from $11000.0 in the prior quarter.
- Over the last five years, Acquisitions for ANIK reached as high as $93.0 million in Q1 2020 and fell as low as $2000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Anika Therapeutics | 198.50 Mn | 131.71 Mn | 19.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 113,000.00 |
| Sep 30, 2021 | 11,000.00 |
| Jun 30, 2021 | 2,000.00 |
| Mar 31, 2021 | 350,000.00 |
| Dec 31, 2020 | 742,000.00 |
| Jun 30, 2020 | 876,000.00 |
| Mar 31, 2020 | 92.98 Mn |